Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Estradiol (ausschl. DaFo GEL), ATC G03CA03 für die Zeit 01.05.26 - 30.04.28 (zzgl. V.-Option 1x12 Monate)

Section 130a, paragraph 8, SGB V enables health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit conducts a regular process of substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned active substance Estradiol (exclusively in the form of GEL), ATC G03CA03, the DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the licensing model for the aforementioned active substance will come into effect for the first time on 01.05.2026 and will end on 30.04.2028 (plus extension option 1x12 months). It will automatically end, regardless, with the entry into force of the exclusive contract.